Deck 20: Screening for Intraepithelial Neoplasia and Cancer of the Lower Genital Tract

Question 1

Intraepithelial neoplasia applies only to abnormal cellular transformation on the cervix.

Answer 1

False

Question 2

Worldwide, types HPV 16 and 58 are responsible for 70% of cervical cancers.

Answer 2

False

Question 3

Women age 30 and older may continue to be screened with cytology alone every 3 years or with HPV testing plus cytology (cotesting) every 5 years.

Answer 3

True

Question 4

Which one of the following is not considered a risk factor for the development of CIN?

A) Women who have human immunodeficiency virus (HIV).
B) Women with other immunosuppressive conditions (e.g., organ transplantation).
C) Women previously treated for cervical intraepithelial neoplasia (CIN) 2, CIN 3, or cancer.
D) Women who have had chlamydia.

Question 5

Management of pregnant women with low-grade squamous intraepithelial lesions (LSIL) includes deferring colposcopic evaluation until 6 weeks postpartum.

Question 6

Unlike atypical squamous cells of undetermined significance (ASC-US) Pap test, the presence of atypical glandular cells Pap test necessitates referral for colposcopy not just a repeat Pap test.

Question 7

The next step in the management of the 24-year-oldwith an ASC-US Pap is:

A) Perform colposcopic examination
B) Perform Pap and HPV cotest in 6 months
C) Perform repeat Pap test in 6 months
D) Perform repeat Pap test in 12 months

Question 8

The next step in the management of women ≥ age 30 who are cytology negative but HPV positive is:

A) Perform colposcopic examination
B) Perform HPV genotyping
C) Perform Pap test in 6 months
D) Repeat cotest in 12 months

Question 9

At what age do you begin Pap test screening?

A) Age 21 and continue every 3 years through age 29
B) Three years after first intercourse
C) At the time of first prenatal visit
D) Age 18 and continue every 3 years through age 29

Question 10

Women with a history of CIN 2 or greater should continue routine screening for at least 10 years after diagnosis, even if that extends beyond age 65?

Question 11

Women who have undergone a total hysterectomy for benign conditions and have not had prior CIN 2 (moderate dysplasia) or CIN 3 (severe dysplasia or carcinoma in situ) may discontinue Pap smear screening.

Question 12

When performing HPV testing, both low-risk and high-risk DNA should be evaluated?